Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza A and B virus infections in February 2018 in Japan. Because of the need to monitor influenza viruses for reduced susceptibility to this drug, we used two cell-based screening systems – a con...

Descripción completa

Detalles Bibliográficos
Autores principales: Takashita, Emi, Morita, Hiroko, Ogawa, Rie, Nakamura, Kazuya, Fujisaki, Seiichiro, Shirakura, Masayuki, Kuwahara, Tomoko, Kishida, Noriko, Watanabe, Shinji, Odagiri, Takato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291754/
https://www.ncbi.nlm.nih.gov/pubmed/30574137
http://dx.doi.org/10.3389/fmicb.2018.03026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291754/
https://www.ncbi.nlm.nih.gov/pubmed/30574137
http://dx.doi.org/10.3389/fmicb.2018.03026

Ejemplares similares